查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
激素避孕藥市場 - 全球行業規模、份額、趨勢、機會和預測，2018-2028 年：按方法、按激素、按地區細分、競爭
市場調查報告書
商品編碼
1255243

激素避孕藥市場 - 全球行業規模、份額、趨勢、機會和預測，2018-2028 年：按方法、按激素、按地區細分、競爭

Hormonal Contraceptives Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Method, By Hormone, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在預測期內，全球激素避孕藥市場預計將出現驚人的增長。

這是由於對口服避孕藥的使用及其預防意外懷孕的有效性以及人口控制的認識提高，這大大增加了世界各地對激素避孕藥的需求。我認為是有的。 此外，激素避孕藥的採用顯著增加以及不同年齡段女性對安全生活意識的增強將進一步增加對各種激素避孕方法的需求，到 2028 年，預計將推動市場增長。 例如，2021 年 4 月，由 Mayne Pharma 上市的屈螺酮和雌四醇組合片劑 Nextstellis 被美國食品和藥物管理局批准用於預防妊娠，成為首批含有天然雌激素的組合片劑之一。 此外，人們對計劃生育的興趣日益濃厚、有利的政府法規以及荷爾蒙避孕藥的進步預計將進□□一步增加對荷爾蒙避孕藥的需求並支持市場的增長。 同樣，各國政府為增加避孕產品所做的支持性努力也將推動預測期內的市場增長。 例如，2019 年 7 月，Allergen Plc 與音樂家兼演員 Ashley Tisdale 合作開展了名為“Women Who Know”的宣傳活動。 世界衛生組織提供了關於使用宮內節育器、黃體酮注射液和植入物等荷爾蒙避孕藥的指南，以幫助高危女性感染艾滋病毒。

意外懷孕增加

影響全球激素避孕藥市場增長的主要因素是城市化進程加快導致計劃生育意識增強，以及對個人生活方式改變的影響。 許多政府機構正在採取措施控制人口規模。 然而，激素避孕藥被認為比避孕套和隔膜等非激素避孕藥更可靠，而且有大量女性人口有計劃外的需求。 這可能會在預測期內推動荷爾蒙避孕藥市場的增長。 根據 PubMed 的一篇文章，美國每年約有 300 萬例意外懷孕。 因此，對計劃外避孕需求的增加顯著增加了需求，進一步推動了預測期內市場的增長。 根據 NCBI 的研究，每 1,000 名正確服用避孕藥的女性中只有 1 人會懷孕。

新型避孕藥的研製

領先的公司正在創新生產副作用較少的可咀嚼的低劑量口服避孕藥。 咀嚼式避孕藥試圖減少副作用，同時讓患者更容易每天使用避孕藥。 開發和銷售可咀嚼的低劑量口服避孕藥的領先公司包括 Lupin Pharmaceuticals、Walter Chilcott 和 Watson Pharmaceuticals。 根據聯合國 2019 年避孕方法調查，在至少五分之一的國家/地區，單一方法佔所有避孕方法的 50% 以上。

近期發展

  • 例如，2021 年 4 月，Mayne Pharma 獲得了美國 FDA 批准用於預防懷孕的 NEXTSTELLIS 和 Estetrol。 它是唯一含有 E4 和植物來源雌激素的避孕藥，與其他雌激素相比幾乎沒有顯著優勢。
  • 例如，2021 年 7 月，MHRA 開始在英國藥店櫃檯銷售避孕藥。 兩個避孕藥品牌，Hana 和 Lovima，只需諮詢您的藥劑師即可在非處方藥店出售去氧孕烯合成黃體酮。
  • 例如，2021 年 6 月，Teva Pharmaceuticals USA 推出了仿製藥 NuvaRing、乙炔雌二醇和依托孕烯陰道環避孕藥。
  • 2020 年 2 月 Agile Therapeutics 的 Twirla 獲得美國 FDA 批准，Twirla 是一種含有左炔諾孕酮和炔雌醇的透皮貼劑。

可自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢

第 4 章 VOC（客戶之聲）

第5章臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成臨床試驗
  • 已完成臨床試驗
  • 管道細分（按開發階段）
  • 管道細分（按狀態）
  • 管道細分（按研究類型）
  • 按地區劃分的渠道細分
  • 臨床試驗熱圖

第 6 章激素避孕藥的全球市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按方法（藥丸、宮內節育器、注射劑、陰道環、植入物等）
    • 按激素分類（聯合激素避孕藥與單獨使用孕激素的比較）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖
    • 通過方法
    • 荷爾蒙
    • 按地區

第 7 章北美激素避孕藥市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 通過方法
    • 荷爾蒙
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 加拿大
    • 墨西哥

第 8 章歐洲激素避孕藥市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 通過方法
    • 荷爾蒙
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第 9 章亞太地區激素避孕藥市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 通過方法
    • 荷爾蒙
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第 10 章南美洲激素避孕藥市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 通過方法
    • 荷爾蒙
    • 按國家
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章中東和非洲激素避孕藥市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 通過方法
    • 荷爾蒙
    • 按國家
  • MEA：國家分析
    • 南非荷爾蒙避孕藥
    • 沙特阿拉伯的荷爾蒙避孕藥
    • 阿聯酋荷爾蒙避孕藥
    • 土耳其荷爾蒙避孕藥
    • 埃及荷爾蒙避孕藥

第 12 章市場動態

  • 司機
  • 任務

第13章市場趨勢與發展

  • 近期趨勢
  • M&A（併購）
  • 產品發布

第14章競爭格局

  • Abbvie, Inc.
  • Afaxys, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bayer AG
  • Merck & Co. Inc.
  • Organon Group of Companies
  • Pfizer Inc.
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc.
  • Pregna International Ltd.

第 15 章戰略建議

簡介目錄
Product Code: 14350

The Global Hormonal Contraceptives Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing awareness regarding the usage of oral contraceptives and their benefits for preventing unintended pregnancy, and population control significantly increased the demand for hormonal contraceptives across different parts of the globe. Additionally, the adoption of hormonal contraceptives has significantly increased, and increasing awareness among women of different age groups for leading a safe life is further expected to increase the demand for different hormonal contraceptive procedures, thereby fuelling the market growth through 2028. For instance, in April 2021, the Food and Drug Administration approved a combination of drospirenone and estetrol tablet Nextstellis marketed by Mayne Pharma for preventing pregnancy, one of the first combination pills containing naturally occurring estrogen. Furthermore, increasing focus on family planning, favorable regulations by the government, and advancements in hormonal contraception are further expected to increase the demand for hormonal contraceptives, thereby supporting the market growth. Similarly, supportive initiatives by various governments to increase contraceptive products will propel the growth of the market during the forecast period. For instance, in July 2019, Allergen Plc collaborated with Ashley Tisdale, a musician, and actress, for the awareness campaign "Women Who Know." The World Health Organization provided guidelines, for the usage of hormonal contraceptives, such as intrauterine devices, progestogen injectables, and implants, for women at greater risk of HIV.

Increasing Number of Unplanned Pregnancies

The main factors that affect the growth of the global hormonal contraceptives market are the increasing awareness of family planning due to growing urbanization growing g influence on the changing lifestyle of individuals. Many government organizations are taking initiatives to control the population size. However, hormonal contraceptives are considered more reliable than non-hormonal contraceptives such as condoms and diaphragms, and there is a huge chunk of the female population with unplanned needs. This in turn may help the hormonal contraceptives market grow during the forecast period. As per a publication in PubMed, the number of unintended pregnancies in the U.S. is around three million annually. So, the growing unplanned need for contraceptives significantly increased the demand, which is further boosting the growth of the market in the forecast period. According to NCBI research, only 1 woman out of 1000 women gets pregnant if they take these contraceptives properly.

Development of New Contraceptives

Major companies are innovating to manufacture chewable low-dose oral contraceptives that reduce side effects. The chewable contraceptive initiative was an attempt to reduce side effects while at the same time making it easier for the patients to get into a daily regimen of using this contraceptive. Some of the top companies that develop and sell chewable low-dose oral contraceptives are Lupin pharmaceuticals, Walter Chilcott, and Watson pharmaceuticals. According to the United Nations Contraceptive Use by Method 2019 study, a single method accounts for 50% or more of all contraceptive use in at least one out of every five nations or regions.

Market Segmentation

The global hormonal contraceptive market can be segmented by method, hormone, and region. Based on the method, the market can be segmented into Pills, Intrauterine Devices, Injectables, Vaginal rings, implants, and Others. Based on hormones, the market can be divided into Combination Hormonal Contraceptives v/s Progestin Only. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global hormonal contraceptives market on account of increasing unplanned pregnancies with low-cost product in the country.

Market Players

Abbvie, Inc., Afaxys, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Merck & Co. Inc., Organon Group of Companies, Pfizer Inc., Johnson & Johnson, Lupin Pharmaceuticals Inc., Pregna International Ltd. are some of the leading players operating in the Global Hormonal Contraceptives Market.

Recent Developments

  • For instance, in April 2021, Mayne Pharma received U.S. FDA approval for NEXTSTELLIS and estetrol for avoiding pregnancy. It is the only contraceptive pill with E4 and a plant-based estrogen having few important benefits compared to other estrogens.
  • For instance, in July 2021, the MHRA launched the OTC sale of contraceptive pills in U.K. pharmacies. Two contraceptive pill brands, Hana and Lovima, are selling desogestrel- synthetic progesterone, OTC, with a brief consultation with a pharmacist.
  • For instance, in June 2021, Teva Pharmaceuticals USA launched the generic form of NuvaRing, Ethinyl estradiol, and etonogestrel vaginal ring contraceptive.
  • In February 2020, Agile Therapeutics, Inc. received U.S. FDA approval for the Twirla, a transdermal patch containing levonorgestrel and Ethinylestradiol.

Report Scope

In this report, global hormonal contraceptives market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hormonal Contraceptives Market, By Method:

  • Pill
  • Intrauterine Device
  • Injectable
  • Vaginal Ring
  • Implant
  • Others

Hormonal Contraceptives Market, By Hormone:

  • Combination Hormonal Contraceptives
  • Progestin Only

Hormonal Contraceptives Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Hormonal Contraceptives Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Hormonal Contraceptives Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others)
    • 6.2.2. By Hormone (Combination Hormonal Contraceptives v/s Progestin Only)
    • 6.2.3. By Region
    • 6.2.4. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Method
    • 6.3.2. By Hormone
    • 6.3.3. By Region

7. North America Hormonal Contraceptives Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Method
    • 7.2.2. By Hormone
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Hormonal Contraceptives Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Method
        • 7.3.1.2.2. By Hormone
    • 7.3.2. Canada Hormonal Contraceptives Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Method
        • 7.3.2.2.2. By Hormone
    • 7.3.3. Mexico Hormonal Contraceptives Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Method
        • 7.3.3.2.2. By Hormone

8. Europe Hormonal Contraceptives Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Method
    • 8.2.2. By Hormone
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Hormonal Contraceptives Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Method
        • 8.3.1.2.2. By Hormone
    • 8.3.2. Germany Hormonal Contraceptives Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Method
        • 8.3.2.2.2. By Hormone
    • 8.3.3. United Kingdom Hormonal Contraceptives Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Method
        • 8.3.3.2.2. By Hormone
    • 8.3.4. Italy Hormonal Contraceptives Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Method
        • 8.3.4.2.2. By Hormone
    • 8.3.5. Spain Hormonal Contraceptives Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Method
        • 8.3.5.2.2. By Hormone

9. Asia-Pacific Hormonal Contraceptives Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Method
    • 9.2.2. By Hormone
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Hormonal Contraceptives Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Method
        • 9.3.1.2.2. By Hormone
    • 9.3.2. India Hormonal Contraceptives Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Method
        • 9.3.2.2.2. By Hormone
    • 9.3.3. Japan Hormonal Contraceptives Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Method
        • 9.3.3.2.2. By Hormone
    • 9.3.4. South Korea Hormonal Contraceptives Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Method
        • 9.3.4.2.2. By Hormone
    • 9.3.5. Australia Hormonal Contraceptives Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Method
        • 9.3.5.2.2. By Hormone

10. South America Hormonal Contraceptives Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Method
    • 10.2.2. By Hormone
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Hormonal Contraceptives Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Method
        • 10.3.1.2.2. By Hormone
    • 10.3.2. Argentina Hormonal Contraceptives Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Method
        • 10.3.2.2.2. By Hormone
    • 10.3.3. Colombia Hormonal Contraceptives Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Method
        • 10.3.3.2.2. By Hormone

11. Middle East and Africa Hormonal Contraceptives Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Method
    • 11.2.2. By Hormone
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Hormonal Contraceptives Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Method
        • 11.3.1.2.2. By Hormone
    • 11.3.2. Saudi Arabia Hormonal Contraceptives Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Method
        • 11.3.2.2.2. By Hormone
    • 11.3.3. UAE Hormonal Contraceptives Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Method
        • 11.3.3.2.2. By Hormone
    • 11.3.4. Turkey Hormonal Contraceptives Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Method
        • 11.3.4.2.2. By Hormone
    • 11.3.5. Egypt Hormonal Contraceptives Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Method
        • 11.3.5.2.2. By Hormone

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Abbvie, Inc.
    • 14.6.2. Afaxys, Inc.
    • 14.6.3. Teva Pharmaceuticals Industries Ltd.
    • 14.6.4. Bayer AG
    • 14.6.5. Merck & Co. Inc.
    • 14.6.6. Organon Group of Companies
    • 14.6.7. Pfizer Inc.
    • 14.6.8. Johnson & Johnson
    • 14.6.9. Lupin Pharmaceuticals Inc.
    • 14.6.10. Pregna International Ltd.

15. Strategic Recommendations